<DOC>
	<DOCNO>NCT02930187</DOCNO>
	<brief_summary>Evaluate correlation validate 12 joints-Naredo ultrasound score ( B-mode ( 0-3 ) , PD ( 0-3 ) PDUS ( 0-3 , max B-mode PD ) ) DAS28-ESR , DAS28-CRP , CDAI , SDAI ACR-EULAR criterion remission routine care .</brief_summary>
	<brief_title>Ultrasound Evaluation Remission Rheumatoid Arthritis</brief_title>
	<detailed_description>Clinical remission realistic goal manage rheumatoid arthritis ( RA ) treat target strategy assess accord different composite score ( DAS28 , Simplified Disease Activity Index ( SDAI ) , Clinical Disease Activity Index ( CDAI ) , ACR-EULAR 2011 remission ) . There , however , validate ultrasound remission criterion continue uncertainty signification persistent synovial hypertrophy B-mode Power Doppler ( PD ) mode RA patient clinical remission . The objective evaluate correlation validate 12 joints-Naredo ultrasound score ( B-mode ( 0-3 ) , PD ( 0-3 ) PDUS ( 0-3 , max B-mode PD ) ) DAS28-ESR , DAS28-CRP , CDAI , SDAI ACR-EULAR criterion remission routine care . This french multicenter cross-sectional study take place 11 rheumatology department . The inter intra-observer reproducibility ultrasound score good excellent . Inclusion criterion follow : RA meeting ACR-EULAR criterion , &lt; 15 year progression , DAS-28-ESR &lt; 2.6 least 3 month , stable treatment include corticoid necessary ( equivalent prednisone &lt; 0.1 mg/kg ) 6 month . A standardized US examination perform experience ultrasonographist blind clinical data . Spearman 's correlation coefficient determine Naredo12 B-mode ( min-max,0-36 ) , PD mode ( 0-36 ) PDUS ( 0-36 ) score different clinical remission score . The impact disease duration duration clinical remission ultrasound score also assess ( Kruskall-Wallis 's test ) .</detailed_description>
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<criteria>Adults ( âged 18 ) , Rheumatoid arthritis accord ACREULAR 2010 criterion , less 10 year least Remission accord DAS28VS ( &lt; 2.6 ) since 3 month least , Disease modify antirheumatic drug and/or biotherapy stable dose since 6 month least Steroids ≤0.1 mg/kg/day without high dose last 3 month Oral write information consent Patient participate clinical trial rheumatoid arthritis treatment Patient administrative supervision</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>Rheumatoid arthritis , remission , ultrasound</keyword>
</DOC>